Panthera Biopartners
Chris Dodd is the Chief Commercial Officer at Panthera Biopartners. Chris has over 17 years of experience in the medical device and pharmaceutical industry. Chris has held various sales and business development positions at companies such as ArthroCare Corporation, Olympus KeyMed, and CareFusion. In their most recent role as Executive Vice President BD at Panthera Bio, Chris was responsible for leading sales and marketing activities across biotech and biopharmaceutical partnerships globally. Chris has a proven track record of success in building and developing high-performing teams and is passionate about creating value for patients and customers.
Chris Dodd's educational career began with a Bachelor of Science in Biomedicine from Leeds Beckett University. Chris continued their education at Yorkshire Martyrs.
This person is not in any offices
Panthera Biopartners
1 followers
Panthera Biopartners, established in 2019, is a leading UK-based Site Management Organisation (SMO) specialising in patient recruitment and the execution of clinical trials across various therapeutic areas. Founded by Dr Ian Smith, the originator of Synexus, and Professor John Lyon, a former global executive at Covance, Panthera has rapidly expanded its network to include dedicated clinical trial sites in major UK cities such as Glasgow, London, Manchester, Preston, Sheffield and York The organisation's mission is to enhance healthcare accessibility by conducting clinical research that integrates diverse insights and expertise. Panthera is committed to maintaining rigorous ethical standards and contributing to medical advancements that positively impact health and well-being. Panthera's management team comprises experienced professionals with extensive knowledge in conducting clinical trials across multiple therapy areas and countries. Key figures include Dr Ian Smith (Co-Founder, Director, and Chief Medical Officer), Stuart Young (Chief Executive Officer), and Chris Dodd (Chief Commercial Officer). In October 2024, Panthera became the first UK clinical trial site organisation to join Parexel’s Site Alliance Vaccine Network, a global consortium of high-performing clinical trial sites. This collaboration underscores Panthera's exceptional performance in patient recruitment and its strong partnership with Parexel. Panthera's dedication to innovation and excellence was recognised in October 2023 when it was named Pharma Research Centre of the Year at the Pharma Industry Awards UK. The award highlighted Panthera's innovative SMO model, which emphasises rapid start-up times, access to a vast pool of prequalified patients, and the digitisation of patient engagement processes.